Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer
BackgroundIn Switzerland, approximately 6000 new breast cancer cases and 1300 deaths are reported annually. Brain metastasis from breast cancer (BMBC) has a major effect on prognosis. This study aimed to identify prognostic factors for overall survival (OS) in a cohort of Swiss patients with BMBC. T...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1247402/full |
| _version_ | 1827813667823943680 |
|---|---|
| author | Dimitri Dettwiler Elena-Diana Chiru Eveline Daetwyler Vérène Dougoud-Chauvin Markus W. Gross Christian Kurzeder Alfred Zippelius Andreas Schötzau Marcus Vetter Marcus Vetter Marcus Vetter Marcus Vetter |
| author_facet | Dimitri Dettwiler Elena-Diana Chiru Eveline Daetwyler Vérène Dougoud-Chauvin Markus W. Gross Christian Kurzeder Alfred Zippelius Andreas Schötzau Marcus Vetter Marcus Vetter Marcus Vetter Marcus Vetter |
| author_sort | Dimitri Dettwiler |
| collection | DOAJ |
| description | BackgroundIn Switzerland, approximately 6000 new breast cancer cases and 1300 deaths are reported annually. Brain metastasis from breast cancer (BMBC) has a major effect on prognosis. This study aimed to identify prognostic factors for overall survival (OS) in a cohort of Swiss patients with BMBC. This study evaluated the prognosis on older BMBC, which has not been completely addressed in the literature.MethodsWe performed a retrospective chart review analysis with the primary endpoint of OS after a diagnosis of BMBC. The study population was divided into 2 groups based on an OS cut-off value of 12 months after diagnosis. Univariate and multivariate analyses of several risk factors, including age, were performed. To evaluate differences in OS according to age, we performed a secondary analysis to examine the prognostic value of clinical symptoms, metastatic pattern, and lymph node involvement in an older (≥65 years) vs. younger (<65 years) cohort.ResultsFrom 1989 to 2019, 55 patients were identified as having BMBC, among whom 47 patients were confirmed to be dead. The median patient age was 58 years (range 25–83 years). Comorbidities were present in 45 (81.8%) patients. The median survival in the OS <12 and OS ≥12 months groups was 4.3 and 30.7 months, respectively (p<0.001). Multivariate analysis revealed no significant differences in terms of comorbidities, medication use, M-stage, and symptomatology between the 2 groups. Additionally, there was no significant difference in OS in the 2 subgroups of patients aged <65 and ≥65 years.DiscussionWe concluded that age should not be a decisive factor in therapy planning for advanced breast cancer patients with BMBC. |
| first_indexed | 2024-03-11T23:35:24Z |
| format | Article |
| id | doaj.art-dba5da9ff3b7439594f2e71c7e821db8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T23:35:24Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dba5da9ff3b7439594f2e71c7e821db82023-09-20T04:50:40ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.12474021247402Clinical and pathological factors and outcome of central nervous system metastasis in breast cancerDimitri Dettwiler0Elena-Diana Chiru1Eveline Daetwyler2Vérène Dougoud-Chauvin3Markus W. Gross4Christian Kurzeder5Alfred Zippelius6Andreas Schötzau7Marcus Vetter8Marcus Vetter9Marcus Vetter10Marcus Vetter11Department of Medical Oncology, University Hospital Basel, Basel, SwitzerlandCancer Center, Medical University Clinics, Kantonsspital Baselland, Liestal, SwitzerlandDepartment of Medical Oncology, University Hospital Basel, Basel, SwitzerlandDepartment of Medical Oncology, Kantonsspital HFR Freiburg, Fribourg, SwitzerlandDepartment of Radiooncology, University Hospital Basel, Basel, SwitzerlandBreast Center, University Hospital Basel, Basel, SwitzerlandDepartment of Medical Oncology, University Hospital Basel, Basel, SwitzerlandDepartment of Gynecologic Oncology, University Hospital Basel, Basel, SwitzerlandDepartment of Medical Oncology, University Hospital Basel, Basel, SwitzerlandBreast Center, University Hospital Basel, Basel, SwitzerlandCancer Center Baselland, Medical University Clinic Baselland, Liestal, SwitzerlandCancer Center, Medical University Clinics, Kantonsspital Baselland, Liestal, SwitzerlandBackgroundIn Switzerland, approximately 6000 new breast cancer cases and 1300 deaths are reported annually. Brain metastasis from breast cancer (BMBC) has a major effect on prognosis. This study aimed to identify prognostic factors for overall survival (OS) in a cohort of Swiss patients with BMBC. This study evaluated the prognosis on older BMBC, which has not been completely addressed in the literature.MethodsWe performed a retrospective chart review analysis with the primary endpoint of OS after a diagnosis of BMBC. The study population was divided into 2 groups based on an OS cut-off value of 12 months after diagnosis. Univariate and multivariate analyses of several risk factors, including age, were performed. To evaluate differences in OS according to age, we performed a secondary analysis to examine the prognostic value of clinical symptoms, metastatic pattern, and lymph node involvement in an older (≥65 years) vs. younger (<65 years) cohort.ResultsFrom 1989 to 2019, 55 patients were identified as having BMBC, among whom 47 patients were confirmed to be dead. The median patient age was 58 years (range 25–83 years). Comorbidities were present in 45 (81.8%) patients. The median survival in the OS <12 and OS ≥12 months groups was 4.3 and 30.7 months, respectively (p<0.001). Multivariate analysis revealed no significant differences in terms of comorbidities, medication use, M-stage, and symptomatology between the 2 groups. Additionally, there was no significant difference in OS in the 2 subgroups of patients aged <65 and ≥65 years.DiscussionWe concluded that age should not be a decisive factor in therapy planning for advanced breast cancer patients with BMBC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1247402/fullmetastatic breast cancerbrain metastasismeningeal carcinomatosisolder patients with breast cancerlong-term survivors with breast cancer and brain metastases |
| spellingShingle | Dimitri Dettwiler Elena-Diana Chiru Eveline Daetwyler Vérène Dougoud-Chauvin Markus W. Gross Christian Kurzeder Alfred Zippelius Andreas Schötzau Marcus Vetter Marcus Vetter Marcus Vetter Marcus Vetter Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer Frontiers in Oncology metastatic breast cancer brain metastasis meningeal carcinomatosis older patients with breast cancer long-term survivors with breast cancer and brain metastases |
| title | Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer |
| title_full | Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer |
| title_fullStr | Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer |
| title_full_unstemmed | Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer |
| title_short | Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer |
| title_sort | clinical and pathological factors and outcome of central nervous system metastasis in breast cancer |
| topic | metastatic breast cancer brain metastasis meningeal carcinomatosis older patients with breast cancer long-term survivors with breast cancer and brain metastases |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1247402/full |
| work_keys_str_mv | AT dimitridettwiler clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT elenadianachiru clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT evelinedaetwyler clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT verenedougoudchauvin clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT markuswgross clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT christiankurzeder clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT alfredzippelius clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT andreasschotzau clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT marcusvetter clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT marcusvetter clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT marcusvetter clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer AT marcusvetter clinicalandpathologicalfactorsandoutcomeofcentralnervoussystemmetastasisinbreastcancer |